The immune system loses its ability to distinguish between a real threat and a false alarm
En los laboratorios del University College London, un equipo de inmunólogos ha descubierto el mecanismo molecular por el cual una proteína llamada PTPN22 actúa como regulador de precisión en las células T del sistema inmunitario. Cuando esta proteína falla, el equilibrio entre defensa y daño se rompe: el cuerpo puede atacar sus propios tejidos o dejar escapar células tumorales. Este hallazgo, publicado en Science Signaling, no es solo un avance técnico, sino una nueva comprensión de cómo la vida se protege a sí misma sin destruirse en el intento.
- Las células T sin PTPN22 se vuelven hipersensibles, reaccionando a señales débiles que deberían ignorar y desencadenando daño en tejidos sanos.
- La acumulación anormal de actina F y la concentración excesiva de la proteína adaptadora PSTPIP1 revelan un citoesqueleto que se reorganiza de forma descontrolada.
- Mutaciones en el gen que codifica PTPN22 aparecen repetidamente en pacientes con lupus y artritis reumatoide, conectando por fin la genética con el mecanismo celular.
- Los investigadores apuntan ahora a aprovechar este conocimiento para diseñar células T más eficaces contra tumores sin sacrificar la precisión que evita el daño colateral.
- El descubrimiento abre una vía concreta para mejorar las inmunoterapias contra el cáncer y los tratamientos de enfermedades autoinmunes mediante el ajuste fino de la activación inmune.
Un equipo de inmunólogos del University College London ha identificado el papel central de la proteína PTPN22 en la regulación de las células T, los soldados de primera línea del sistema inmunitario. Cuando estas células detectan una amenaza, deben formar una sinapsis inmunológica —un canal de comunicación directo— que exige una reorganización precisa de su esqueleto interno. PTPN22 es la molécula que calibra ese proceso: sin ella, el equilibrio se rompe.
Al comparar células T normales con células carentes de esta proteína, los investigadores observaron que en las deficientes la actina F se acumulaba de forma anómala y la proteína adaptadora PSTPIP1 se concentraba en exceso en los puntos de activación. El resultado eran células hipersensibles, capaces de reaccionar ante señales que deberían ignorar, causando daño donde no debería haberlo. Este mecanismo explica algo que los genetistas habían notado durante años: las mutaciones en el gen de PTPN22 aparecen con frecuencia en pacientes con lupus y artritis reumatoide.
Pero las implicaciones van más allá de las enfermedades autoinmunes. Las células cancerosas son expertas en silenciar la respuesta inmune, y comprender cómo PTPN22 ajusta la activación de las células T podría permitir diseñar terapias que potencien la respuesta contra tumores sin perder la precisión necesaria para no atacar tejido sano. El hallazgo, publicado en Science Signaling, recuerda que el sistema inmunitario no es simplemente un arma que hay que afilar, sino un instrumento de precisión que apenas estamos aprendiendo a tocar.
A team of immunologists at University College London has mapped out a crucial molecular brake on the immune system—one that, when it fails, can trigger both cancer and autoimmune disease. The discovery, published in Science Signaling, centers on a protein called PTPN22 and its role in controlling how T cells reshape themselves when they encounter a threat.
T cells are the immune system's frontline soldiers. When they spot a target—a virus, a tumor cell, a foreign invader—they need to form what scientists call an immunological synapse: a direct communication channel that lets them coordinate their attack. But forming that synapse requires the cell's internal skeleton to reorganize, a process that must be precise. Too little response and the threat escapes. Too much, and the immune system turns on the body's own tissues. PTPN22 is the molecule that calibrates this balance.
The researchers compared normal T cells with ones lacking PTPN22 and watched what happened when the cells were activated. In the deficient cells, something went wrong. A structural protein called actin F accumulated abnormally, and another adapter protein, PSTPIP1, clustered in unusual concentrations where T-cell receptors gather. The result was a cytoskeleton that remodeled itself too aggressively, making the cells hypersensitive to weak signals they should have ignored. In practical terms, these T cells became trigger-happy—reacting to stimuli that normal cells would dismiss, unleashing damage they shouldn't.
This finding explains something that geneticists had noticed for years: mutations in the gene that codes for PTPN22 show up repeatedly in patients with lupus and rheumatoid arthritis, two diseases where the immune system attacks the body's own tissues. The protein's job is to prevent exactly that kind of overreaction. When it's broken or absent, the immune system loses its ability to distinguish between a real threat and a false alarm.
But the implications extend beyond autoimmune disease. Cancer cells are masters at hiding from the immune system, and one of their tricks is dampening T-cell responses. If researchers can understand how PTPN22 fine-tunes immune activation, they might be able to engineer T cells that respond more effectively to tumors while still maintaining the precision needed to avoid collateral damage. The discovery opens a path toward improving cancer immunotherapies—treatments that harness the immune system's own power to fight malignancy.
The work is a reminder that the immune system is not simply a weapon to be sharpened. It is a finely tuned instrument, and understanding its mechanisms at this molecular level is how we learn to play it better.
Notable Quotes
The protein adjusts immune signaling networks with precision and prevents excessive activation of cell receptors, avoiding uncontrolled reactions that attack healthy tissue— University College London research team
The Hearth Conversation Another angle on the story
Why did the researchers focus on this particular protein? What made them think PTPN22 was worth studying?
Geneticists had already found that mutations in the gene for PTPN22 appear in lupus and rheumatoid arthritis patients. So the protein was already on the radar as something important for immune control. The researchers wanted to understand the actual mechanism—how the protein does its job at the cellular level.
And what did they find when they looked?
When T cells lacked PTPN22, their internal skeleton didn't remodel properly during activation. Structural proteins piled up in the wrong places, and the cells became hypersensitive to weak signals. They were essentially overreacting to everything.
So the protein is a kind of governor on the immune response?
Exactly. It prevents the system from spinning out of control. Without it, T cells can't distinguish between a real threat and noise. They attack indiscriminately.
How does this help with cancer?
Cancer cells are good at suppressing immune responses. If we can understand how to properly activate T cells—how to make them respond strongly to tumors without losing precision—we might design better immunotherapies. The protein shows us where that balance point is.
And the autoimmune side?
If we can restore or enhance PTPN22 function, we might be able to calm down immune cells that are attacking healthy tissue. It's the opposite problem, but the same molecule is central to both.